Table 1.
Baseline characteristics of Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) patients and controls.
Figure 1.
Glucagon-like peptide 1 (GLP-1) secretion in response to oral glucose tolerance test (oGTT).
(A) GLP-1 secretion in response to oGTT is significantly decreased in patients vs. controls (p<0.001). Patients n = 52; controls n = 50. (B) GLP-1 secretion in NAFLD and NASH vs. controls. NAFLD n = 16; NASH n = 36; controls n = 50. GLP-1 (pmol/ml) is expressed as mean±SEM.
Table 2.
Secretion of Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), insulin and glucagon and glucose disposal in patients with NAFLD and NASH vs. controls in response to oral glucose tolerance test.
Table 3.
Secretion of Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), insulin and glucagon and glucose disposal in NAFLD and NASH subgroups vs. controls in response to oral glucose tolerance test.
Figure 2.
Glucose-dependent insulinotropic polypeptide (GIP) secretion in response to oGTT.
(A) GIP secretion in response to oGTT is not different in patients vs. controls. Patients n = 52; controls n = 28. (B) GIP secretion in NAFLD and NASH vs. controls. NAFLD n = 16; NASH n = 36; controls n = 28. GIP (pg/ml) is expressed as mean±SEM.
Figure 3.
Glucose, insulin and glucagon concentrations in response to oGTT.
Plasma glucose (A, B), insulin (C, D) and glucagon (E, F) concentration curves are shown for patients vs. controls (A, C, E) and NAFLD and NASH vs. controls (B, D, F). Patients n = 52 (NAFLD n = 16; NASH n = 36); controls n = 50. Glucose (mmol/l), insulin (µU/ml) and glucagon (pg/ml) are expressed as mean±SEM.